Back to MPT Database

EVO100 Gel

Evofem is collaborating with Orion Biotechnology to evaluate the combination of Orion’s novel CCR5 antagonist, OB-002, and Phexxi® with the goal of developing a Multipurpose Prevention Technology (MPT) product candidate for indications including the prevention of human immunodeficiency virus (HIV) in women.

Development Stage:

Clinical – Phase 3 Trial (C3)



Delivery Route & Method:

Topical - Gel-Vaginal

Mechanism of Action:

Vaginal pH modulator


  • Evofem Biosciences, Inc.


  • Evofem Biosciences, Inc.

Funding Mechanism:

The Phase 3 EVOGUARD study is funded in part by a strategic investment in Evofem by Adjuvant Capital, LLC.

Back to MPT Database